ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

NCT00598481 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Immunologic Deficiency Syndromes

Interventions

GENETIC: Gene Therapy
DRUG: Busulfan

Sponsor

Fondazione Telethon